

# Maciej Jurynczyk

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4828687/publications.pdf>

Version: 2024-02-01

25  
papers

2,211  
citations

471061

17  
h-index

610482

24  
g-index

26  
all docs

26  
docs citations

26  
times ranked

2275  
citing authors

#	ARTICLE	IF	CITATIONS
1	Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 269-279.	1.8	3
2	Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 217-227.	1.4	24
3	Increasing role of imaging in differentiating MS from non-MS and defining indeterminate borderline cases. <i>Neurologia i Neurochirurgia Polska</i> , 2022, 56, 210-219.	0.6	4
4	Towards imaging criteria that best differentiate MS from NMOSD and MOGAD: large multi-ethnic population and different clinical scenarios. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103778.	0.9	5
5	Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD – No. <i>Multiple Sclerosis Journal</i> , 2021, 27, 15-16.	1.4	5
6	Classifying the antibody-negative NMO syndromes. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2019, 6, e626.	3.1	17
7	Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. <i>Practical Neurology</i> , 2019, 19, 187-195.	0.5	78
8	Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. <i>JAMA Neurology</i> , 2018, 75, 478.	4.5	306
9	Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 132-136.	0.9	132
10	Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 165-169.	0.9	37
11	Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. <i>Brain</i> , 2017, 140, 617-627.	3.7	208
12	Clinical presentation and prognosis in MOG-antibody disease: a UK study. <i>Brain</i> , 2017, 140, 3128-3138.	3.7	527
13	Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease. <i>Acta Neuropathologica Communications</i> , 2017, 5, 95.	2.4	35
14	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. <i>Journal of Neurology</i> , 2016, 263, 140-149.	1.8	60
15	MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2015, 2, e89.	3.1	322
16	EXPERT OPINIONS ON THE DIAGNOSIS AND TREATMENT OF PATIENTS WITH AQP4-NEGATIVE NMO/MS OVERLAPPING SYNDROMES. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, e4.40-e4.	0.9	0
17	Heat shock protein 70 (Hsp70) interacts with the Notch1 intracellular domain and contributes to the activity of Notch signaling in myelin-reactive CD4 T cells. <i>Journal of Neuroimmunology</i> , 2015, 287, 19-26.	1.1	7
18	Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 20-25.	0.9	72

#	ARTICLE	IF	CITATIONS
19	Natalizumab and the development of extensive brain lesions in neuromyelitis optica. <i>Journal of Neurology</i> , 2013, 260, 1919-1921.	1.8	23
20	Notch: A new player in MS mechanisms. <i>Journal of Neuroimmunology</i> , 2010, 218, 3-11.	1.1	58
21	Immune regulation of multiple sclerosis by transdermally applied myelin peptides. <i>Annals of Neurology</i> , 2010, 68, 593-601.	2.8	74
22	Hypoglycemia as a trigger for the syndrome of acute bilateral basal ganglia lesions in uremia. <i>Journal of the Neurological Sciences</i> , 2010, 297, 74-75.	0.3	21
23	Overcoming failure to repair demyelination in EAE: $\hat{I}^3$ -secretase inhibition of Notch signaling. <i>Journal of the Neurological Sciences</i> , 2008, 265, 5-11.	0.3	39
24	Notch3 Inhibition in Myelin-Reactive T Cells Down-Regulates Protein Kinase $C\hat{I}_3$ and Attenuates Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2008, 180, 2634-2640.	0.4	73
25	Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005, 170, 3-10.	1.1	80